Answers are grounded in this paper and cite their sources.
Limited experience with the use of urethane in the treatment of leukemia indicates that this substance presents a considerable promise as a palliative agent in chronic myelogenous leukemia. It has no apparent value in the treatment of acute leukemia. Further extensive observation will be necessary to provide a true measure of the clinical usefulness of this preparation.
No takes yet. Share an insight, caveat, or question.
Watkins et al. (1948) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: